Immunovant Inc (NAS:IMVT)
$ 26 -0.6 (-2.26%) Market Cap: 3.80 Bil Enterprise Value: 3.16 Bil PE Ratio: 0 PB Ratio: 6.13 GF Score: 42/100

Immunovant Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 12, 2020 / 03:15PM GMT
Release Date Price: $49.14 (+0.02%)
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Everyone, welcome to the last day of our healthcare conference at Crédit Suisse. My name is Tiago Fauth, mid-cap biotech analyst here at Crédit Suisse. And I'm joined today by the Immunovant team. They're going to do a presentation. Feel free to e-mail me any questions, and I'll try to work those in towards the end.

But for now, that's it, I think. Pete, you can take it away.

Peter Salzmann
Immunovant, Inc. - CEO & Director

Super. Thanks, Tiago. Let me just share my screen here. You see that, okay?

Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Yes.

Peter Salzmann
Immunovant, Inc. - CEO & Director

Excellent. So I just want to briefly touch on our safe harbor presentation statement. This is on our website, this entire presentation is on our website, and I will be making some forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot